Kramer, N.J., Carlomagno, Y., Zhang, Y.J., Almeida, S., Cook, C.N., Gendron, T.F., Prudencio, M., Van Blitterswijk, M., Belzil, V., Couthouis, J., Paul, J.W., Goodman, L.D., Daughrity, L., Chew, J., Garrett, A., Pregent, L., Jansen-West, K., Tabassian, L.J., Rademakers, R., Boylan, K., Graff-Radford, N.R., Josephs, K.A., Parisi, J.E., Knopman, D.S., Petersen, R.C., Boeve, B.F., Deng, N., Feng, Y., Cheng, T.H., Dickson, D.W., Cohen, S.N., Bonini, N.M., Link, C.D., Gao, F.B., Petrucelli, L., Gitler, A.D. (2016). Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts.  Science 353(6300): 708--712.

FBrf0233374

Research paper

An expanded hexanucleotide repeat in C9orf72 causes amyotrophic lateral sclerosis and frontotemporal dementia (c9FTD/ALS). Therapeutics are being developed to target RNAs containing the expanded repeat sequence (GGGGCC); however, this approach is complicated by the presence of antisense strand transcription of expanded GGCCCC repeats. We found that targeting the transcription elongation factor Spt4 selectively decreased production of both sense and antisense expanded transcripts, as well as their translated dipeptide repeat (DPR) products, and also mitigated degeneration in animal models. Knockdown of SUPT4H1, the human Spt4 ortholog, similarly decreased production of sense and antisense RNA foci, as well as DPR proteins, in patient cells. Therapeutic targeting of a single factor to eliminate c9FTD/ALS pathological features offers advantages over approaches that require targeting sense and antisense repeats separately.

PMC5823025 (PMC) (EuropePMC)